A few months after getting FDA approval for human trials, Neuralink is looking for its first test subjects. The Verge reports: The six-year initial trial, which the Elon Musk-owned company is calling “the PRIME Study,” is intended to test Neuralink tech designed to help those with paralysis control devices. The company is looking for people (PDF) with quadriplegia due to vertical spinal cord injury or ALS who are over the age of 22 and have a “consistent and reliable caregiver” to be part of the study.
The PRIME Study (which apparently stands for Precise Robotically Implanted Brain-Computer Interface, even though that acronym makes no sense) is set to research three things at once. The first is the N1 implant, Neuralink’s brain-computer device. The second is the R1 robot, the surgical robot that actually implants the device. The third is the N1 User App, the software that connects to the N1 and translates brain signals into computer actions. Neuralink says it’s planning to test both the safety and efficacy of all three parts of the system.
Those who participate in the PRIME Study will first participate in an 18-month study that involves nine visits with researchers. After that, they’ll spend at least two hours a week on brain-computer interface research sessions and then do 20 more visits over the next five years. Neuralink doesn’t say how many subjects it’s looking for or when it plans to begin the study but does say it only plans to compensate “for study-related costs” like travel to and from the study location. (Also not clear: where that location is. Neuralink only says it has received approval from “our first hospital site.”)
